Publikationen in Zusammenarbeit mit Forschern von University of British Columbia (4)

2022

  1. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384

2018

  1. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalanprednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

    Haematologica, Vol. 103, Núm. 9, pp. 1518-1526

  2. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet Haematology, Vol. 5, Núm. 11, pp. e563-e598

2016

  1. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial

    The Lancet, Vol. 387, Núm. 10027, pp. 1551-1560